2m 2m 2m 2m 2m 2m 2m
ALUMIS (ALMS)
NASDAQ
$20.30+$0.26 (+1.27%)
Price as of Jun 03, 2026 6:12 PM EDT- $2.7BMarket Cap
- 480.87%1-Year Change
- BiotechnologyIndustry
ALUMIS (ALMS)
$20.30+$0.26 (+1.27%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 17.4M N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 17.4M N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -1.1M +25.44% | -912,000 N/A | |
Depreciation and Amortization Expense | 3.5M +10.91% | 3.2M N/A | |
Total Operating Expenses | 477.9M +58.89% | 300.8M N/A | |
Operating Profit | -453.8M +50.89% | -300.8M N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 201.9M +2,996.43% | 6.5M N/A | |
Income before Taxes | -251.9M -16.25% | -300.8M N/A | |
Income Taxes | -8.6M N/A | 0 N/A | |
Extraordinary Items | 529,000 N/A | N/A N/A | |
Net Income | -243.3M -17.30% | -294.2M N/A | |
Net Income from Continuing Operations Applicable to Common | -251.9M -14.39% | -294.2M N/A | |
Basic EPS and Net Income | -2.86 -72.45% | -10.38 N/A | |
Diluted EPS and Net Income | -2.86 -72.45% | -10.38 N/A | |
Basic Weighted Average Shares | 85.0M +200.01% | 28.3M N/A | |
Diluted Weighted Average Shares | 85.0M +200.01% | 28.3M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 89.7M -47.11% | 169.5M N/A | |
Short-Term Investments | 218.8M +84.30% | 118.7M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 308.5M +7.02% | 288.3M N/A | |
Total Current Assets | 318.2M +3.93% | 306.2M N/A | |
Accumulated Depreciation | 8.0M +75.29% | 4.6M N/A | |
Property and Plant and Equipment and Net | 18.2M -13.25% | 21.0M N/A | |
Total Long-Term Assets | 6.3M +89,714.29% | 7,000 N/A | |
Total Assets | 411.9M +20.81% | 341.0M N/A | |
Income Taxes Payable | 2.1M N/A | 0 N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 73.3M +44.01% | 50.9M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 207,000 -99.29% | 29.2M N/A | |
Total Liabilities | 110.6M +36.79% | 80.9M N/A | |
Retained Earnings | -901.9M +36.95% | -658.6M N/A | |
Total Stockholders Equity | 301.3M +15.84% | 260.1M N/A | |
Total Shares Outstanding | 99.1M +109.82% | 47.2M N/A | |
Cash Flow | |||
Cash from Operating Activities | -369.5M +44.87% | -255.1M N/A | |
Capital Expenditures | 653,000 -62.30% | 1.7M N/A | |
Cash from Investing Activities | 287.9M +352.99% | -113.8M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 2.1M -99.58% | 492.4M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | -2,609.72% N/A | N/A N/A | |
Return on Assets | -64.63% N/A | N/A N/A | |
Return on Equity | -86.68% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 4.34 N/A | N/A N/A | |
Cash Ratio | 1.22 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow